Optimizing Urine Drug Monitoring in an Evolving Clinical Landscape
Wednesday, Nov. 11, 2026
11 a.m.–Noon CT
Cost
Free for all participants.
Overview
Controlled substance monitoring in urine has evolved substantially as prescribing practices, polysubstance use, regulatory expectations, and laboratory technologies have changed. Increasing use of gabapentin and pregabalin, greater recognition of polysubstance use, and broader adoption of definitive mass spectrometry have reshaped how clinicians evaluate medication adherence, unexpected results, and patient safety.
This webinar reviews the evidence supporting modern urine drug monitoring, compares immunoassay, definitive, and hybrid testing strategies, and provides practical guidance for selecting testing based on clinical scenarios. Through case studies, participants will learn how to interpret common findings and how an integrated testing portfolio can support pain management, controlled substance monitoring, addiction medicine, and other practice settings.
Presenter
Paul Jannetto, Ph.D.
Co-director, Clinical & Forensic Toxicology Lab, Metals Lab, and Clinical Mass Spectrometry Lab
Professor of Laboratory Medicine and Pathology
Division of Clinical Biochemistry
Mayo Clinic, Rochester, Minnesota
Learning objectives
Upon completion of this activity, participants should be able to:
- Describe current clinical, regulatory, and epidemiologic trends influencing urine drug monitoring.
- Compare presumptive immunoassay, definitive mass spectrometry, and hybrid testing approaches, including their strengths and challenges.
- Select appropriate urine drug testing strategies based on patient risk, clinical indication, and practice setting.
- Apply evidence-based interpretation principles to common clinical scenarios involving opioids, benzodiazepines, stimulants, alcohol biomarkers, and gabapentinoids.
Intended audience
This webinar is appropriate for primary care physicians, internal medicine physicians, nurse practitioners, physician assistants, laboratory directors, lab supervisors, medical laboratory scientists, and laboratory send-out coordinators/managers.
Credit
The following types of credit are offered for this event:
ASCLS P.A.C.E.®
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
State of Florida
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Clinical Chemistry/UA/Toxicology) credit. This program has been approved for 1.0 contact hour.
To obtain credit
To obtain credit:
- Register for and participate in the program.
- Complete the evaluation that will be sent to you after the program.
- Generate and print your certificate(s)
Level of instruction for this program is intermediate.
Faculty disclosure
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Questions
Contact us: mcleducation@mayo.edu
